Eagle Bioscience’s GLP-2 ELISA Assay Kit was highlighted in recent publication! The scientists in this study induced the physiological secretion of GLP-2 via nanoparticles to help them develop a combination therapy for inflammatory bowel disease (IBD). Check out the abstract and full article below.


Current treatments for inflammatory bowel disease (IBD) treatment consist of anti-inflammatory products. In this study, we sought to induce the physiological secretion of glucagon-like peptide 2, a peptide with intestinal growth-promoting activity, via nanoparticles while simultaneously providing with immunomodulation by tailoring the nanoparticle surface. To this end, we developed hybrid lipid hyaluronate-KPV conjugated nanoparticles loaded with teduglutide for combination therapy in IBD. The nanocarriers induced (or did not induce) immunosuppression depending on the presence (or absence) of a hyaluronan-KPV functionalization. This strategy holds promise as a nanoparticle platform for combined mucosal healing and immunomodulation in IBD treatment.

V. Marotti, et al. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment, Bioactive Materials, Volume 32, 2024, Pages 206-221, ISSN 2452-199X, https://doi.org/10.1016/j.bioactmat.2023.09.014.

If you have any questions about the GLP-2 ELISA Assay Kit or any of our other offerings contact us here.